This trial is active, not recruiting.

Condition postherpetic neuralgia
Treatments adl5747, placebo, pregabalin
Phase phase 2
Sponsor Cubist Pharmaceuticals
Collaborator Pfizer
Start date January 2010
End date August 2011
Trial size 92 participants
Trial identifier NCT01058642, 40CL234


The primary purpose of this study is to evaluate the analgesic efficacy of ADL5747 in patients with postherpetic neuralgia (PHN). The secondary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of ADL5747.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model crossover assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
ADL5747 150 mg twice daily
ADL5747 150 mg twice daily for 2 weeks
(Placebo Comparator)
twice daily
twice daily
(Active Comparator)
Pregabalin 150 mg twice daily
pregabalin Lyrica
pregabalin 75 mg twice daily for the first 3 days, increased to 150 mg twice daily for the last 11 days of the 2 week treatment period, followed by a dose of pregabalin 75 mg twice daily for 3 days as a taper period

Primary Outcomes

Change in weekly average numeric pain rating scale (NPRS) score from baseline to end of treatment (Week 2 of each treatment period)
time frame: Week 2

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Key inclusion Criteria: - have a diagnosis of PHN (defined as pain present for at least 3 months after the healing of herpes zoster rash; there is no upper limit on the duration of PHN) - have an average daily pain score of at least 4 on the numeric pain rating scale (0-10) for Visits 2 and 3 - be willing and able to understand and comply with protocol requirements, dietary and dosing regimens, and other protocol instructions and restrictions (eg, forgo use of their normal pain medication and other protocol specified prohibited medications for the duration of the study) - for male subjects, be surgically sterile or agree to use an appropriate method of contraception or have a sexual partner who is surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive approved and deemed highly effective by the United States Food and Drug Administration (FDA) from the first dose of study medication through 30 days after the last dose of study medication on Day 49 - for female subjects of childbearing potential, be using an insertable, injectable, transdermal, or combination oral contraceptive approved and deemed highly effective by the FDA from the first dose of study medication through 30 days after the last dose of study medication on Day 49 and have negative results on a serum pregnancy test during Visit 1 and on a urine pregnancy test during Visit 3 (women who are surgically sterile [eg, hysterectomy, tubal ligation] or postmenopausal [if ≥ 55 years old, no menses for at least 2 years; if < 55 years old, follicle stimulating hormone concentrations within the postmenopausal range of > 40 mIU/mL and 17 β estradiol levels of < 37 pg/mL] are also eligible to participate) Key exclusion Criteria: - be pregnant - have significant skin lesions that could interfere with pain assessment - have a history of seizures or a history of abnormal electroencephalographic results at any time (subjects with a history of febrile seizures before the age of 6 years may be enrolled) - have had previous neurolytic or neurosurgical therapy for PHN - have had a treatment that included local anesthetic nerve blocks within 30 days before Visit 2 (Day 7) - have any other type of pain that may impair the self-assessment of pain due to PHN - have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant renal, hepatic, hematologic, cardiovascular, metabolic, gastrointestinal, neurologic, psychiatric, or other condition that would preclude participation in the study - have an active malignancy of any type (subjects with a history of successfully treated malignancy > 5 years before the scheduled first dose of study medication and subjects with treated basal or squamous cell cancer may be enrolled) - have a medical history or condition that may interfere with drug absorption (eg, stomach resection) - be currently using protocol specified prohibited medications in the absence of appropriate washout - be currently taking moderate or strong inhibitors or inducers of cytochrome P450-3A (CYP3A) or inhibitors of P glycoprotein transporters - have an estimated glomerular filtration rate (GFR) that is less than or equal to 60 mL/min calculated by the Cockcroft Gault equation or have alanine aminotransferase and/or aspartate aminotransferase levels that are at least 2 times the upper limit of normal - have a history of substance abuse or dependence within the previous 5 years, including alcohol or positive results on the urine drug screen at Visit 1, 2, or 3; subjects may be enrolled if positive results are due to medication(s) prescribed for the subject and permitted by the protocol - have a history of suicide attempts or be judged clinically to be at serious risk of suicide - have a score of more than 29 on the Beck Depression Inventory-II at Visit 1 - have a history of allergy to acetaminophen (the rescue medication for this study) - have a history of intolerance to pregabalin or documented failure to respond to a maximally tolerated dose of pregabalin - have ever received the investigational drug ADL5747 or have participated in any clinical study involving an investigational product in which they received that product within 30 days before the scheduled administration of study medication for this study

Additional Information

Official title A Phase 2A, Randomized, Blinded, Placebo and Active Controlled, 2 Period Crossover Study to Assess the Analgesic Efficacy, Safety, and Tolerability of ADL5747 in Subjects With Postherpetic Neuralgia
Trial information was received from ClinicalTrials.gov and was last updated in June 2011.
Information provided to ClinicalTrials.gov by Cubist Pharmaceuticals.